Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
894.4(c) 922.2(c) 907.8(c) 888.6(c) 893.6 Last
529 961 329 109 196 790 721 222 321 878 Volume
-1.32% +3.11% -1.56% -2.12% +0.56% Change
More quotes
Financials (DKK)
Sales 2018 2 967 M
EBIT 2018 1 450 M
Net income 2018 1 387 M
Finance 2018 5 793 M
Yield 2018 -
Sales 2019 4 238 M
EBIT 2019 2 396 M
Net income 2019 2 242 M
Finance 2019 7 765 M
Yield 2019 -
P/E ratio 2018 39,34
P/E ratio 2019 24,77
EV / Sales2018 16,8x
EV / Sales2019 11,3x
Capitalization 55 727 M
More Financials
Company
Genmab A/S operates as an international biotechnology company.The firm develops human antibody therapeutics for the treatment of cancer.Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.The company was founded by Donald Lee Drakeman,... 
Sector
Biotechnology & Medical Research
Calendar
10/20 | 12:30pmPresentation
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
10/17GENMAB : Announces Net Sales of DARZALEX for Third Quarter of 2018
AQ
10/17GENMAB : Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2018
AQ
10/16Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 20..
GL
10/09GENMAB : and Seattle Genetics Announce Tisotumab Vedotin Data to be Presented at..
AQ
10/05GENMAB A/S : has published its Articles of Association
AQ
10/01GENMAB : 2018 Capital Markets Day
AQ
09/26GENMAB : 2018 Capital Markets Day
AQ
09/25GENMAB : Grant of Restricted Stock Units and Warrants to Genmab employees
AQ
09/25GENMAB : Financial Calendar for 2019
AQ
09/22GENMAB : Grant of Restricted Stock Units and Warrants to Genmab employees
AQ
More news
Sector news : Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/17$GEN A/S GENMAB BUY - TOP PICKS | DKK1262 Price renegotiations have weighed .. 
10/12$GEN A/S 1 director bought: A director at Genmab AS bought 1,200 shares at 9.. 
10/11#Genmab article from start 2017  
10/10#Genmab below 880 will flush lower - look for 750 and i'm starting to be inte.. 
10/09Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented a.. 
More tweets
Qtime:24
News from SeekingAlpha
10/12Key events next week - healthcare 
09/25Recent analyst action in Europe - healthcare 
08/31Darzalex combo therapy OK'd in Europe for first-line multiple myeloma 
08/11Genmab A/S (GNMSF) CEO Jan van de Winkel on Q2 2018 Results - Earnings Call T.. 
08/09Genmab A/S 2018 Q2 - Results - Earnings Call Slides 
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 1 339  DKK
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Pernille Lyngvold Erenbjerg Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB-11.78%8 632
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671